Browsing by Author "Damy, Thibaud (6506337417)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases(2021) ;Garcia-Pavia, Pablo (57197883068) ;Rapezzi, Claudio (7005883289) ;Adler, Yehuda (7005992564) ;Arad, Michael (7004305446) ;Basso, Cristina (7004539938) ;Brucato, Antonio (7006007796) ;Burazor, Ivana (24767517700) ;Caforio, Alida L.P. (7005166754) ;Damy, Thibaud (6506337417) ;Eriksson, Urs (7102875592) ;Fontana, Marianna (16306839900) ;Gillmore, Julian D. (7003539031) ;Gonzalez-Lopez, Esther (56453004900) ;Grogan, Martha (7004085182) ;Heymans, Stephane (6603326423) ;Imazio, Massimo (55787131200) ;Kindermann, Ingrid (6603127742) ;Kristen, Arnt V. (7801324099) ;Maurer, Mathew S. (35515053700) ;Merlini, Giampaolo (7006059649) ;Pantazis, Antonis (6508359030) ;Pankuweit, Sabine (7003360984) ;Rigopoulos, Angelos G. (6701402043)Linhart, Ales (7004149017)Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice. © European Society of Cardiology 2021 - Some of the metrics are blocked by yourconsent settings
Publication Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases(2021) ;Garcia-Pavia, Pablo (57197883068) ;Rapezzi, Claudio (7005883289) ;Adler, Yehuda (7005992564) ;Arad, Michael (7004305446) ;Basso, Cristina (7004539938) ;Brucato, Antonio (7006007796) ;Burazor, Ivana (24767517700) ;Caforio, Alida L. P (7005166754) ;Damy, Thibaud (6506337417) ;Eriksson, Urs (7102875592) ;Fontana, Marianna (16306839900) ;Gillmore, Julian D (7003539031) ;Gonzalez-Lopez, Esther (56453004900) ;Grogan, Martha (7004085182) ;Heymans, Stephane (6603326423) ;Imazio, Massimo (55787131200) ;Kindermann, Ingrid (6603127742) ;Kristen, Arnt V (7801324099) ;Maurer, Mathew S (35515053700) ;Merlini, Giampaolo (7006059649) ;Pantazis, Antonis (6508359030) ;Pankuweit, Sabine (7003360984) ;Rigopoulos, Angelos G (6701402043)Linhart, Ales (7004149017)Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice. © The Author(s), 2021. - Some of the metrics are blocked by yourconsent settings
Publication The Heart Failure Association Atlas: rationale, objectives, and methods(2020) ;Seferović, Petar M. (6603594879) ;Jankowska, Ewa (21640520500) ;Coats, Andrew J.S. (35395386900) ;Maggioni, Aldo P. (57203255222) ;Lopatin, Yuri (6601956122) ;Milinković, Ivan (51764040100) ;Polovina, Marija (35273422300) ;Lainščak, Mitja (9739432000) ;Timmis, Adam (7006508725) ;Huculeci, Radu (35344805500) ;Vardas, Panos (57206232389) ;Berger, Rudolf (55697214700) ;Jahangirov, Tofiq (8048714300) ;Kurlianskaya, Alena (57195936081) ;Troisfontaines, Pierre (7801598602) ;Droogne, Walter (6603404035) ;Dizdarević Hudić, Larisa (26431864200) ;Tokmakova, Mariya (55409365000) ;Glavaš, Duška (15762332500) ;Barberis, Vassilis (55890808700) ;Spinar, Jindrich (55941877300) ;Wolsk, Emil (36626530100) ;Uuetoa, Tiina (36524214200) ;Tolppanen, Heli (32668130000) ;Damy, Thibaud (6506337417) ;Kipiani, Zviad (57201421880) ;Störk, Stefan (6603842450) ;Keramida, Kalliopi (57202300032) ;Habon, Tamas (6603051363) ;Gotsman, Israel (57203083288) ;Weinstein, Jean-Marc (7201816859) ;Jona Ingimarsdottir, Inga (57215673069) ;Crowley, Jim (7202580077) ;Dalton, Barbra (57214795585) ;Aspromonte, Nadia (6602892060) ;Rakisheva, Amina (58038558000) ;Mirrakhimov, Erkin (57216202888) ;Kamzola, Ginta (56695275300) ;Skouri, Hadi (21934953600) ;Celutkiene, Jelena (6507133552) ;Noppe, Stephanie (57194588406) ;Jovanova, Silvana (16432657000) ;Vataman, Eleonora (23476033300) ;Pogorevici Cobac, Irina (57215657141) ;Van Pol, Petra (6506579816) ;de Boer, Rudolf A. (8572907800) ;von Lueder, Thomas (16176815600) ;Straburzyńska-Migaj, Ewa (57206994261) ;Moura, Brenda (6602544591) ;Chioncel, Ovidiu (12769077100) ;Fomin, Igor (7005059642) ;Begrambekova, Julia (57215669147) ;Mareev, Yuri (55673633100) ;Goncalvesova, Eva (55940355200) ;Garcia Pinilla, José Manuel (59157660600) ;Lindmark, Krister (6603147424) ;Ruschitzka, Frank (7003359126) ;Mueller, Christian (58068181500) ;Cavusoglu, Yuksel (7003632889) ;Gardner, Roy (7401524087)Voronkov, Leonid (6603737599)Heart failure (HF) constitutes the growing cardiovascular burden and the major public health issue, but comprehensive statistics on HF epidemiology and related management in Europe are missing. The Heart Failure Association (HFA) Atlas has been initiated in 2016 in order to close this gap, representing the continuity directly rooted in the European Society of Cardiology (ESC) Atlas of Cardiology. The major aim of the HFA Atlas is to establish a contemporary dataset on HF epidemiology, resources and reimbursement policies for HF management, organization of the National Heart Failure Societies (NHFS) and their major activities, including education and HF awareness. These data are gathered in collaboration with the network of NHFS of the ESC member and ESC affiliated countries. The dataset will be continuously improved and advanced based on the experience and enhanced understanding of data collection in the forthcoming years. This will enable revealing trends, disparities and gaps in knowledge on epidemiology and management of HF. Such data are highly needed by the clinicians of different specialties (aside from cardiologists and cardiac surgeons), researchers, healthcare policy makers, as well as HF patients and their caregivers. It will also allow to map the snapshot of realities in HF care, as well as to provide insights for evidence-based health care policy in contemporary management of HF. Such data will support the ESC/HFA efforts to improve HF management ant outcomes through stronger recommendations and calls for action. This will likely influence the allocation of funds for the prevention, treatment, education and research in HF. © 2020 European Society of Cardiology
